Showing 2891-2900 of 5685 results for "".
- Novartis to File for New Lucentis (Ranibizumab) Indication in Retinopathy of Prematurity (ROP)https://modernod.com/news/novartis-to-file-for-new-lucentis-ranibizumab-indication-in-retinopathy-of-prematurity-rop/2479845/Novartis announced results from a phase 3 study of Lucentis (ranibizumab) versus laser surgery (the current standard of care) in premature infants with retinopathy of prematurity (ROP). Unlike laser surgery, which damages eye tissue and can be associated with significant complications such as hig
- Hoya Launches 4-in-1 Multisert Preloaded Delivery System with Vivinex IOLhttps://modernod.com/news/hoya-launches-4-in-1-multisert-preloaded-delivery-system-with-vivinex-iol/2479847/Hoya Surgical Optics officially launched the new multiSert 4-in-1 preloaded delivery system with Vivinex IOL at the European Society of Cataract and Refractive Surgeons (ESCRS) in Vienna, Austria. “MultiSert is
- Novartis to Cut Over 2000 Jobs in Switzerland, UKhttps://modernod.com/news/novartis-to-cut-over-2000-jobs-in-switzerland-uk/2479850/Novartis announced that it will slash more than 2,000 jobs by 2022, including eliminating 1,700 positions in Switzerland and around 400 roles in the UK, as it looks to increase profitability. The move comes as the company consolidates manufacturing and shifts positions elsewhere as part of plans
- Cigna Now Covering Avedro’s FDA-Approved Cross-Linking Procedurehttps://modernod.com/news/cigna-now-covering-avedros-fda-approved-cross-linking-procedure/2479851/Avedro announced that 50 commercial insurance plans now cover Avedro’s FDA-approved corneal cross-linking procedure, following Cigna’s recent announcement that it is covering the Photrexa drug formulations and the KXL System used in the treatment of progressive keratoconus. Other health plans rec
- Excel-Lens Announces CE Mark Approval for CAPSULaser Selective Laser Capsulotomy (SLC) Devicehttps://modernod.com/news/excel-lens-announces-ce-mark-approval-for-capsulaser-selective-laser-capsulotomy-slc-device/2479872/Excel-Lens announced the CE mark approval of CAPSULaser, a selective laser that creates a capsulotomy during cataract surgery in just over a second. The laser energy is delivered in a continuous manner rather than a pulsed beam which can create tissue bridges. In clinical studies, CAPSULas
- LumiThera to Debut Valeda Light Delivery System at EURETINAhttps://modernod.com/news/lumithera-to-debut-valeda-light-delivery-system-at-euretina/2479887/LumiThera announced that it will debut the Valeda Light Delivery System for the treatment of dry AMD in the exhibition hall at the EURETINA meeting in Vienna. It will also host a symposium on photobiomodulation (PBM) technology entitled, “Photobiomodulation: An Innovative, Mitochondria-targ
- Clearside Biomedical to Present Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitishttps://modernod.com/news/clearside-biomedical-to-present-pivotal-phase-3-peachtree-clinical-trial-in-macular-edema-associated-with-non-infectious-uveitis/2479896/Clearside Biomedical announced that data from PEACHTREE, its pivotal phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Rahul N. Khurana, MD, an investigator for PEACHTREE, Partner at Northern California Retina Vitreo
- Alcon to Move Headquarters from Texas to Switzerland Following Proposed Spinoff From Novartishttps://modernod.com/news/alcon-to-move-headquarters-from-texas-to-switzerland-following-proposed-spinoff-from-novartis/2479901/Alcon announced plans to locate its future global headquarters in Geneva, Switzerland, following completion of its proposed spinoff from Novartis, which is expected to be completed in the first half of 2019. Alcon’s new global headquarters in Geneva will be the primary location for A
- MeiraGTx Announces AAV-CNGA3 Granted Rare Pediatric Disease Designation by the U.S. FDA for the Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cnga3-granted-rare-pediatric-disease-designation-by-the-u-s-fda-for-the-treatment-of-achromatopsia/2479906/Gene therapy company MeiraGTx Holdings announced that the FDA has granted rare pediatric disease designation to the company’s gene therapy product candidate AAV-CNGA3 for the treatment of patients with achromatopsia (ACHM) due to mutations in the CNGA3 gene. ACHM is an inherited r
- UK Calls on Drugmakers to Stockpile 6-Week Supply of Medicines to Cope With “No Deal” Brexithttps://modernod.com/news/uk-calls-on-drugmakers-to-stockpile-6-week-supply-of-medicines-to-cope-with-no-deal-brexit/2479911/The UK’s Department of Health and Social Care has asked pharmaceutical companies that supply drugs to NHS patients to “ensure they have a minimum of six weeks additional supply” of medicines, over and above their usual buffer stocks, in case imports from the EU are disrupted in